Table 3.
Data regarding pain control and radiologic response. RT = radiotherapy; CHT = chemotherapy; BED10 = biologically effective dose (assuming an α/β ratio of 10).
| Pain Control (per n of Lesions) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| At End of Radiotherapy | |||||||||||
| Complete control | Partial control | No control | Total | ||||||||
| Overall | 193 (35.9%) | 277 (51.5%) | 68 (12.6%) | 538 | |||||||
| RT alone | 70 (34%) | 102 (49.5%) | 34 (16.5%) | 206 | |||||||
| Concurrent CHT | 29 (39.7%) | 35 (47.9%) | 9 (12.3%) | 73 | |||||||
| Concurrent biological agent | 94 (36.3%) | 140 (54.1%) | 25 (9.7%) | 259 | |||||||
| BED10 < 15 Gy | 11 (39.3%) | 6 (21.4%) | 11 (39.3%) | 28 | |||||||
| BED10 15–38 Gy | 51 (34.5%) | 71 (48%) | 26 (17.6%) | 148 | |||||||
| BED10 > 38 Gy | 131 (36.2%) | 200 (55.2%) | 31 (8.6%) | 362 | |||||||
| At 1 Month after Radiotherapy | |||||||||||
| Complete control | Partial control | No control | Total | ||||||||
| Overall | 244 (66.5%) | 112 (30.5%) | 11 (3%) | 367 | |||||||
| RT alone | 105 (75.5%) | 31 (22.3%) | 3 (2.2%) | 139 | |||||||
| Concurrent CHT | 17 (56.7%) | 13 (43.3%) | 0 (0%) | 30 | |||||||
| Concurrent biological agent | 122 (61.6%) | 68 (34.3%) | 8 (4%) | 198 | |||||||
| BED10 < 15 Gy | 14 (56%) | 11 (44%) | 0 (0%) | 25 | |||||||
| BED10 15–38 Gy | 56 (60.9%) | 34 (37%) | 2 (2.2%) | 92 | |||||||
| BED10 > 38 Gy | 174 (69.6%) | 67 (26.8%) | 9 (3.6%) | 250 | |||||||
| At 3 Months after Radiotherapy | |||||||||||
| Complete control | Partial control | No control | Total | ||||||||
| Overall | 261 (73.5%) | 83 (23.4%) | 11 (3.1%) | 355 | |||||||
| RT alone | 108 (80.6%) | 25 (18.7%) | 1 (0.7%) | 134 | |||||||
| Concurrent CHT | 17 (58.6%) | 12 (41.4%) | 0 (0%) | 29 | |||||||
| Concurrent biological agent | 136 (70.8%) | 46 (24%) | 10 (5.2%) | 192 | |||||||
| BED10 < 15 Gy | 14 (66.7%) | 7 (33.3%) | 0 | 21 | |||||||
| BED10 15–38 Gy | 58 (64.4%) | 28 (31.1%) | 4 (4.4%) | 90 | |||||||
| BED10 > 38 Gy | 189 (77.5%) | 48 (19.7%) | 7 (2.9%) | 244 | |||||||
| At 6 Months after Radiotherapy | |||||||||||
| Complete control | Partial control | No control | Total | ||||||||
| Overall | 271 (77%) | 60 (17%) | 21 (6%) | 352 | |||||||
| RT alone | 109 (79.6%) | 20 (14.6%) | 8 (5.8%) | 137 | |||||||
| Concurrent CHT | 19 (67.9%) | 9 (32.1%) | 0 (0%) | 28 | |||||||
| Concurrent biological agent | 143 (76.5%) | 31 (16.6%) | 13 (7%) | 187 | |||||||
| BED10 < 15 Gy | 15 (71.4%) | 5 (23.8%) | 1 (4.7%) | 21 | |||||||
| BED10 15–38 Gy | 65 (73.9%) | 19 (21.6%) | 4 (4.5%) | 88 | |||||||
| BED10 > 38 Gy | 192 (78.7%) | 36 (14.8%) | 16 (6.6%) | 244 | |||||||
| Radiological Response at 6 Months (n of Lesions) | |||||||||||
| Complete response | Partial response | Stable disease | Disease progression | Total | |||||||
| Overall | 16 (8.8%) | 127 (70.2%) | 30 (16.6%) | 8 (4.4%) | 181 | ||||||
| RT alone | 8 (11.8%) | 43 (63.2%) | 10 (14.7%) | 7 (10.3%) | 68 | ||||||
| Concurrent CHT | 0 (0%) | 9 (69.2%) | 4 (30.8%) | 0 (0%) | 13 | ||||||
| Concurrent biological agent | 8 (8%) | 75 (75%) | 16 (16%) | 1 (1%) | 100 | ||||||
| BED10 < 15 Gy | 2 (18.2%) | 3 (27.3%) | 4 (36.4%) | 2 (18.2%) | 11 | ||||||
| BED10 15–38 Gy | 8 (25.8%) | 13 (41.9%) | 9 (29%) | 1 (3.2%) | 31 | ||||||
| BED10 > 38 Gy | 6 (4.3%) | 111 (79.9%) | 17 (12.2%) | 5 (3.6%) | 139 | ||||||